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The atypical Nef protein (NefF12) from human immunodeficiency virus type 1 strain F12 (HIV-1F12) inter-
feres with virion production and infectivity via a mysterious mechanism. The correlation of these effects with
the unusual perinuclear subcellular localization of NefF12 suggested that the wild-type Nef protein could bind
to assembly intermediates in late stages of viral replication. To test this hypothesis, Nef from HIV-1NL4-3 was
fused to an endoplasmic reticulum (ER) retention signal (NefKKXX). This mutant NefKKXX protein reca-
pitulated fully the effects of NefF12 on Gag processing and virion production, either alone or as a CD8 fusion
protein. Importantly, the mutant NefKKXX protein also localized to the intermediate compartment, between
the ER and the trans-Golgi network. Furthermore, Nef bound the GagPol polyprotein in vitro and in vivo. This
binding mapped to the C-terminal flexible loop in Nef and the transframe p6* protein in GagPol. The
significance of this interaction was demonstrated by a genetic assay in which the release of a mutant HIV-1
provirus lacking the PTAP motif in the late domain that no longer binds Tsg101 was rescued by a Nef.Tsg101
chimera. Importantly, this rescue as well as incorporation of Nef into HIV-1 virions correlated with the ability
of Nef to interact with GagPol. Our data demonstrate that the retention of Nef in the intermediate compart-
ment interferes with viral replication and suggest a new role for Nef in the production of HIV-1.
Human immunodeficiency virus type 1 (HIV-1), the caus-
ative agent of AIDS, encodes 16 distinct proteins that are
expressed differentially during the viral replicative cycle. Ini-
tially, the early regulatory proteins Tat and Rev and the so-
called negative effector (Nef) are translated from multiply
spliced mRNA species. During late phases, singly spliced or
unspliced transcripts direct the expression of viral accessory
proteins (viral proteins R and U [Vpr and Vpu] and viral
infectivity factor [Vif]), as well as structural group-specific an-
tigen (Gag), Gag and polymerase (GagPol), and envelope
(Env) polyproteins (see reference 20 and references therein).
The expression of Gag and GagPol is regulated tightly by
ribosomal frameshifting that enables the precursor polypro-
teins to be expressed from the same unspliced genomic mRNA
(25). Frameshifting is promoted by a “slippery” sequence (U
UUU UUA), which occurs at the junction between nucleocap-
sid (NC) and the spacer peptide (p1) of Gag and ensures that
only 5% of the transcripts give rise to GagPol (1, 5). The
55-kDa Gag polypeptide contains matrix (MA), capsid (CA),
NC, and the viral late domain (p6), in addition to the spacer
peptides p1 and p2 (MA-CA-p2-NC-p1-p6). The 160-kDa
GagPol precursor consists of MA, CA, p2, and NC, followed by
the pol-encoded transframe protein (p6*) and protease (PR),
reverse transcriptase (RT), and integrase (IN) (see references
3 and 44 and references therein). PR cleaves Gag and GagPol
into their structural and enzymatic subunits during the late
stages of viral budding, thereby ensuring maturation to infec-
tious particles (49).
Nef from HIV-1 is a 27- to 32-kDa viral accessory protein
that participates in numerous processes during the viral repli-
cative cycle. It is also incorporated into virions, where Nef is
cleaved by PR (39, 51). Initially, Nef was thought to decrease
viral replication in vitro. Subsequently, because it supports
high levels of viremia and progression to AIDS as well as
induces an AIDS-like disease in transgenic mice, Nef was de-
fined as a key factor for the pathogenesis of primate lentivi-
ruses (9, 10, 22, 24).
Functions of Nef include the removal of CD4 and the major
histocompatibility complex class I molecules from the surface
of infected cells, thereby facilitating viral replication and im-
mune evasion, respectively (20). Moreover, Nef activates sig-
naling cascades that increase levels of viral replication in pri-
mary T cells (11, 14, 44). Finally, Nef increases levels of Gag in
detergent-resistant microdomains (lipid rafts) at the plasma
membrane to enhance the infectivity of progeny virions (53).
Another important clue for a role of Nef during virion pro-
duction came from the finding that the dominant negative Nef
protein from HIV-1F12 (NefF12) interferes with Gag process-
ing, production, and infectivity of other HIV-1 strains in trans
(8, 12, 15, 16, 35). HIV-1F12 was cloned as a provirus from
chronically infected HUT78 cells that produced no virions
(16). Not only was NefF12 primarily responsible for this phe-
notype of HIV-1F12, but it could inhibit the production of other
strains of HIV-1 (8, 12, 15, 35). In those studies, an unusual
localization of NefF12 to a perinuclear compartment corre-
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lated with its interfering phenotype. Together, those studies
suggested that Nef might interact with viral structural compo-
nents during the assembly of HIV-1.
In this study, by placing an endoplasmic reticulum (ER)
retention signal at its C terminus, we forced the retention of a
common Nef protein within the biosynthetic pathway. This
perinuclear retention was instrumental for subsequent inhibi-
tory effects of Nef on Gag processing and virion production,
which correlated with the binding between the C-terminal flex-
ible loop of Nef and p6* from GagPol. Additionally, the mu-
tant Nef protein lacking the flexible loop was no longer incor-
porated into viral particles. Finally, a trans-complementation
assay for virus release provided genetic evidence for the inter-
action between Nef and GagPol. We conclude that Nef binds
viral structural components during the biosynthesis of progeny
virions in the producer cell.
MATERIALS AND METHODS
Antibodies. Monoclonal antihemagglutinin (anti-HA) epitope (F7) (Santa
Cruz Biotechnology, Santa Cruz, Calif.), monoclonal anti-Nef (52), mouse anti-
p24Gag (AG3.0) (referred to as anti-CA throughout), monoclonal anti-RT
(NEA-9304) (New England Nuclear, Boston, Mass.), and polyclonal anti-Rab6
(C-19) (Santa Cruz Biotechnology) antibodies were used as first antibodies to
detect HA epitope-tagged proteins, Nef, Gag, GagPol, and Rab6, respectively.
Secondary horseradish peroxidase-conjugated anti-mouse antibody (Santa Cruz
Biotechnology) was detected by enhanced chemiluminescence (Amersham Bio-
sciences, Evanston, Ill.). Secondary antibodies for immunofluorescence were
from Molecular Probes (Eugene, Oreg.). For immunoprecipitation assays, rabbit
anti-p24Gag polyclonal (ABI) (referred as anti-CApoly throughout), and rabbit
polyclonal anti-HA (Y11) (Santa Cruz Biotechnology) antibodies were used. The
fluorescein isothiocyanate-conjugated anti-CD8 antibody used for immunofluo-
rescence was purchased from Becton Dickinson (San Jose, Calif.).
Plasmid constructions. Plasmid DNAs encoding replication-competent HIV-1
proviruses were from HIV-1NL4-3 (1). The variant NL4-3Nef with nef deleted
was generously provided by John Guatelli, University of California, San Diego.
Expression plasmids for mutant Nef proteins were generated by inserting the nef
genes into the pEF-BOS vector. The nefF12 gene was derived from the HIV-1F12
isolate (16), while NefKKXX was generated by amplifying the nef gene from the
NL4-3 provirus with a reverse primer encoding the KKMP sequence at the 3
end. The Nef expression plasmid was generated from the NL4-3 provirus and
inserted into the pcDNA3.1D (Invitrogen, Carlsbad, Calif.) plasmid at the
TOPO site. This plasmid was used to derive an expression construct for NefFL
(Nef with a deletion in the flexible loop, amino acids 148 to 180) by standard
mutagenesis techniques. The expression plasmid for NefFLKKXX was gener-
ated by amplifying the nef gene from pcDNA3.1D NefFL with a reverse primer
encoding the KKMP sequence at the 3 end. Expression plasmids for hybrid
CD8.Nef proteins were generated by inserting nef genes into the EF-BOS plas-
mid with the extracellular and transmembrane portion of CD8 (28). The expres-
sion plasmid for CD8.NefKKXX was derived from HIV-1NL4-3. GST.Nef and
mutant GST.Nef1-60, GST.Nef55-210, and GST.HIVNefFL hybrid proteins were
derived from HIV-1SF2. nef sequences were amplified by PCR with BamHI (5)
and EcoRI (3) restriction sites and inserted into the pGEX-4T1 vector (Phar-
macia, Piscataway, N.J.). For in vitro translation, GagPol and its truncated
derivatives were generated by PCR from HIV-1HxB2 proviral DNA with a frame-
shift mutation between Gag and GagPol, to ensure the synthesis of GagPol and
no Gag, and a point mutation in the active site of PR (40). Gag was amplified
from HIV-1NL4-3. All sequences were introduced into the T7-plink2 vector (28).
To generate the GagPol provirus, a single point mutation (aspartic acid at
position 25 to alanine) was introduced in the PR active site of HIV-1NL4-3 with
a frameshift mutation that bypassed the p1 and p6. The GagPR provirus was
generated as before, with the addition of a termination codon at the end of the
PR gene. For the generation of Gag/GagPol provirus, the same PR-inactivating
mutation was inserted in HIV-1NL4-3. Gag and GagNef proviruses were gen-
erated by introducing an early termination codon into the pol frames of HIV-
1NL4-3 and HIV-1NL4-3nef, respectively. All mutations were introduced into the
HIV-1NL4-3 backbone by standard PCR mutagenesis. Expression plasmids for
HA epitope-tagged p6* and p6 were generated by inserting the p6* and p6 genes
from HIV-1NL4-3 into the pEF-BOS/HA plasmid.
The plasmids pNL, pNLHXB, pENX, pENX.p6, and pENX.Tsg101 were
generous gifts from Paul Bieniasz (The Rockefeller University, New York, N.Y.)
and are described elsewhere (32). To generate the expression plasmid for the
hybrid Nef.HA.Tsg101, Nef.Tsg101.V5, and NefFL.Tsg101.V5 proteins, nef
genes from HIV-1NL4-3 were inserted into the pEF-BOS or the pcDNA3.1D
vector. The HA epitope tag was placed at the 3 end of the nef gene, followed by
the cellular gene Tsg101. In another scenario, the nef gene was followed by the
cellular gene Tsg101 and the V5 tag was placed at the 3 end.
Cells and transfections. 293T, HeLa, and NIH 3T3 cells were grown in Dul-
becco modified minimal essential medium supplemented with 10% fetal calf
serum and streptomycin-penicillin. Transfections were performed with Lipo-
fectamine (Gibco BRL, Rockville, Md.) according to the manufacturer’s instruc-
tions.
Virus production and Gag processing. To assess the effects of Nef during
virion production, 293T cells were transfected with proviral DNA and Nef ex-
pression plasmids at 1:1 molar ratio. At 48 h posttransfection, cells and cell
culture supernatants were harvested. Cells were lysed in radioimmunoprecipita-
tion assay (RIPA) buffer (150 mM NaCl, 50 mM Tris [pH 7.2], 1% Triton X-100,
0.1% sodium dodecyl sulfate [SDS]), and cleared supernatants were analyzed by
Western blotting for Nef and Gag. Culture supernatants were cleared through a
45-m-pore-size filter (Millipore, Bedford, Mass.) and stored at 80°C or used
directly in infectivity assays. Quantification of virion production was performed
by p24Gag (CA) enzyme-linked immunosorbent assay (ELISA) capture assays
(NEN Life Science Products–Perkin-Elmer, Boston, Mass.) according to the
manufacturer’s instructions.
Isolation of virions and VLPs. Culture supernatants, collected at 48 h after
transfection, were clarified by low-speed centrifugation, followed by ultracentrif-
ugation through a 20% sucrose cushion at 100,000  g for 1.5 h. Pellets were
suspended in 1 phosphate-buffered saline (PBS) overnight at 4°C. Viruses and
virus-like particles (VLPs) were lysed in SDS loading buffer, and viral protein
content was analyzed by Western blotting.
Subcellular localization. The subcellular localization of CD8.Nef fusion pro-
teins was analyzed as described previously (12). Briefly, NIH 3T3 cells were
plated on coverslips overnight and subsequently transfected with 1 g of plasmid
DNA. At 36 h posttransfection, cells were fixed in 3.7% paraformaldehyde for 5
min at room temperature, washed in PBS, and then permeabilized with 0.1%
Triton X-100 in PBS for 3 min at room temperature. After the cells were washed
in PBS, they were blocked in PBS–1% bovine serum albumin for 30 min at room
temperature and then incubated with the appropriate first and secondary anti-
bodies. After extensive washing in PBS, the coverslips were mounted in HistoGel
(Linaris, Bettingen, Germany) and analyzed by using a Leica DM IRBE confocal
laser scanning microscope with a 63 oil objective. Pictures of individual optical
sections were processed with Adobe PhotoShop software.
Protein purification, in vitro translation, and glutathione S-transferase (GST)
pull-down assays. GST.Nef hybrid proteins were expressed in Escherichia coli
strain DH5 and purified by using glutathione-Sepharose beads (Pharmacia)
with a modified lysis buffer (50 mM HEPES [pH 7.8], 100 mM KCl, 1% Triton
X-100, 2 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride, and 1 mg of ly-
sozyme per ml). The purity of GST.Nef hybrid proteins was verified by Coomas-
sie blue staining after SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and
their concentration was determined with a protein assay kit (Bio-Rad, Hercules,
Calif.). 35S-labeled Gag, GagPol, and its truncated derivatives were transcribed
and translated according to the manufacturer’s instructions, using the rabbit
reticulocyte system (TNT; Promega, Madison, Wis.). The quality of translated
proteins was verified by SDS-PAGE and autoradiography.
For in vitro binding assays, 0.5 g of immobilized GST or hybrid GST.Nef
proteins was incubated with 5 l of 35S-labeled proteins for 4 h at 4°C in 750 l
of CHAPS {3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate}
buffer (50 mM Tris-HCl [pH 7.4], 0.05 mM EDTA, 10 mM CHAPS, and protease
inhibitors). The beads were then washed five times in the same buffer and
subjected to SDS-PAGE and autoradiography.
Coimmunoprecipitations. 293T cells were transfected with 1 g of each pro-
viral clone, i.e., Gag, Gag/GagPol, GagPol, or GagPR. At 48 h after the trans-
fection, cells were washed in PBS and lysed in RIPA buffer for 30 min at 4°C.
Clarified lysates from Gag- or GagPR-expressing cells were incubated for 4 h at
4°C with anti-CApoly antibody, followed by incubation with protein A-Sepharose
(Amersham-Pharmacia, Uppsala, Sweden) for 90 min at 4°C. For Gag/GagPol
and GagPol clarified lysates, anti-RT antibody was used. Immunocomplexes
were then precipitated and washed three times in RIPA buffer containing 150
mM NaCl and two times in RIPA buffer containing 500 mM NaCl. Precipitates
were resuspended in SDS sample buffer, boiled for 5 min, and resolved by
SDS-PAGE, followed by Western blotting with anti-Nef antibody. For 293T cells










coexpressing p6* or p6 together with Nef, immunoprecipitations were performed
with the anti-HA polyclonal antibody.
trans-complementation assay for virus release. HeLa cells were transfected
with 1.6 g of pL along with 0.4 g of pENX and pENX-derived plasmids. For
cotransfection of pL and Nef.Tsg101 hybrid proteins, a 2:1 molar ratio was
used. Culture supernatants were collected at 48 h after transfection and clarified
by low-speed centrifugation, followed by ultracentrifugation through a 20%
sucrose cushion at 100,000  g for 1.5 h. Viral protein contents in cell and
particle lysates were analyzed by Western blotting. Aliquots from viral particle
preparations were assayed for RT activity, as described previously (12).
RESULTS
Mutant CD8.NefKKXX and NefF12 chimeras localize to the
intermediate compartment. Previously, we and others have
shown that the interfering action of NefF12 on Gag processing,
virion production, and infectivity correlated with its unusual
perinuclear localization (12, 35). To test the hypothesis that
this localization is mechanistically involved in the F12 phe-
notype, a KKXX sorting motif (lysine, lysine, methionine,
and proline [KKMP]) was inserted at the C terminus of a
CD8.NefNL4-3 hybrid protein (CD8.NefKKXX). KKXX mo-
tifs bind the  subunit of the COP-I coatomer and mediate the
retrieval of cargo from later compartments back to the ER
during biosynthetic transport (7, 26). We analyzed whether the
addition of the KKXX motif to Nef induced a subcellular
localization similar to that of the CD8.NefF12 chimera in NIH
3T3 cells by using confocal microscopy. As expected (12, 35),
the hybrid CD8.F12Nef protein was concentrated in perinu-
clear areas of the cell (Fig. 1A, panel d), while the wild-type
CD8.NefNL4-3 chimera was found throughout the cytoplasm
and at the cell membrane (Fig. 1A, panel g). Importantly, the
subcellular distribution of the mutant CD8.NefKKXX chimera
resembled closely that of the CD8.NefF12 fusion protein and
was clearly distinct from wild-type hybrid CD8.NefNL4-3 pro-
tein (Fig. 1A, panel a), suggesting that the addition of the
KKXX motif resulted in the targeting of the hybrid CD8.Nef
and CD8.NefF12 proteins to the same compartment. To char-
acterize this compartment, costaining with markers for the ER
(not shown) and the trans-Golgi network (TGN) (Rab6) was
performed. As expected, a perinuclear subpopulation of the
CD8.NefNL4-3 chimera localized partially to the TGN (Fig.
1A, panel h [merged in panel i]), with no significant overlap
with markers for the ER in the cytoplasm (data not shown).
Surprisingly, CD8.NefF12 and mutant CD8.NefKKXX chime-
ras colocalized only partially with Rab6 (Fig. 1A, panels e
[merged in panel f] and b [merged in panel c], respectively) and
were not detected at ER structures (data not shown). This
pattern is reminiscent of that described in a recent report,
where a CD8.E19 chimera that contained the KKMP motif at
the C terminus was localized mostly to the intermediate com-
partment and the TGN (27, 45). We conclude that the mutant
CD8.NefKKXX and the CD8.NefF12 chimeras both localized
to the intermediate compartment in cells.
Addition of an ER retention signal creates an interfering
Nef protein. Next, we investigated whether the addition of the
KKXX motif to Nef was sufficient for an F12 phenotype on
virion production. Hybrid mutant CD8.NefKKXX or CD8.
NefF12 proteins were coexpressed with HIV-1NL4-3 proviral
DNA with nef deleted (HIV-1NL4-3Nef) in 293T cells, and
virion production was monitored 2 days later. Quantification of
virion production by CA capture ELISA revealed that the
coexpression of both CD8.Nef chimeras resulted in more than
a 10- to 30-fold reduction of virion production compared with
the expression of HIV-1NL4-3Nef alone (Fig. 1B, left panel;
compare bar 2 with bars 3 and 4). The expression of Gag was
equivalent in these cells (Fig. 1B, right panel, compare lanes 5
to 8). This effect was specific for CD8.NefF12 and mutant
CD8.NefKKXX chimeras and was not observed with the wild-
type CD8.NefNL4-3 fusion protein (reference 12 and data not
shown). Additionally, Western blotting of lysates of the virus-
producing cells revealed that processing of the Gag precursor
was severely affected in the presence of these mutant chimeras
(Fig. 1B, right panel; compare MACA- and CA-related bands
in lanes 5 and 6 with lanes 7 and 8). Thus, effects on Gag
processing and virion production were equivalent. As a control
for the KKXX motif, an AAMP sequence, which no longer
binds to -COP, was also placed at the C terminus of the CD8.
Nef hybrid protein (CD8.NefAAXX). It had no effect on Gag
processing and virion production (data not shown). Impor-
tantly, this block of Gag processing by the CD8.NefF12 chi-
mera was identical to results reported by Fackler et al. (12).
However, another study demonstrated that the presence of
NefF12 in the backbone of HIV-1NL4-3 (HIV-1NL4-3NefF12)
interfered only with processing of MACA (35). Since a single
point mutation can reverse the phenotype of NefF12 (11) and
since neither HIV-1F12 nor mutant HIV-1NL4-3NefF12 viruses
replicate in cells (16, 35), this difference could be explained by
the occurrence of back mutations in the nefF12 gene during
viral propagation. We conclude that a mutant CD8.NefKKXX
chimera can interfere with Gag processing and consequently
virion production in a fashion similar to that of the CD8.
NefF12 fusion protein.
Next, we examined whether mutant NefKKXX and NefF12
proteins without the N-terminal CD8 moiety could reproduce
the same phenotype. The identical KKMP sequence was intro-
duced at the C terminus of Nef from HIV-1NL4-3. To measure
the effect of mutant Nef proteins on virion production more
precisely, we first isolated viral particles and analyzed them by
Western blotting. Indeed, both the mutant NefKKXX and
NefF12 proteins inhibited virion production from the mutant
HIV-1NL4-3Nef provirus (Fig. 1C, top panel; compare lane 2
with lanes 3 and 4). This effect correlated with the marked
reduction of processing of the Gag precursor in the producer
cells (Fig. 1C, left lower panels, lysate). Quantification of virion
production by CA capture ELISA and anti-CA Western blot-
ting demonstrated that the efficiency of this inhibition was only
slightly decreased compared to that with the CD8.Nef chime-
ras (compare Fig. 1B and C, bars 2 with bars 3 and 4). This
inhibition was from 5- to 15-fold as determined by ELISA and
up to 20-fold as determined by Western blotting (Fig. 1C;
compare lane 2 to lanes 3 and 4 in CA capture ELISA and
Western blotting, virion). Again, the expression of Gag was
equivalent in these cells (Fig. 1C, left lower panels, lysate). In
sharp contrast, amounts of Gag were reduced in supernatants
of cells expressing NefF12 and mutant NefKKXX proteins
(Fig. 1C, right upper panel; compare lanes 1 and 2 to lanes 3
and 4, Gag, virion). Next, we confirmed that the mutant Nef
proteins were interfering specifically with Gag processing and
had no effect on Gag gene expression (Fig. 1C, left middle
panel; compare Gag, MACA, and CA bands in lanes 1 and 2
with lanes 3 and 4, lysate). For this experiment, a mutant virus










FIG. 1. (A) The mutant CD8.NefKKXX chimera localizes to the intermediate compartment between the ER and TGN as determined by
confocal microscopy. Shown is the immunostaining of NIH 3T3 cells, which expressed the indicated proteins. The subcellular distribution of
expressed proteins and of the TGN was visualized with fluorescein isothiocyanate-conjugated anti-CD8 (green staining but left black and white for
better resolution) and anti-Rab6 (red staining but left black and white for better resolution) antibodies, respectively. The right panels show the
merge of the two pictures on the left. Cells expressed the hybrid mutant CD8.NefKKXX (a to c), the hybrid CD8.NefF12 (d to f), and the hybrid
CD8.NefNL4-3 (g to i) proteins. (B) The hybrid mutant CD8.NefKKXX protein interferes with virion production and Gag processing in 293T cells.
The mutant CD8.NefKKXX chimera inhibits the production of HIV-1. Left panel, virion production from 293T cells, which expressed HIV-1NL4-3
(bar 1) or HIV-1NL4-3Nef (bar 2) or coexpressed HIV-1NL4-3Nef and CD8.NefF12 (bar 3) or mutant CD8.NefKKXX (bar 4) chimeras, was
measured by CA capture ELISA. Means and standard deviations from three independent experiments are shown. Right panels, Western blotting
of these cell lysates was performed with anti-CA (top panel) and anti-Nef (bottom panel) antibodies. (C). Mutant NefKKXX protein inhibits Gag
processing and virion production. 293T cells expressed HIV-1NL4-3 (bar 1) or mutant HIV-1NL4-3Nef (bar 2) viruses or coexpressed the mutant
HIV-1NL4-3Nef virus and NefF12 (bar 3) or mutant NefKKXX (bar 4) proteins. Viral supernatants and cell lysates (lysate) were monitored for
CA as described for panel B (left panels). Additionally, anti-CA Western blotting was performed on viral supernatants (virion). As controls, effects
of NefF12 and NefKKXX on VLPs were analyzed (lanes 5 to 8). 293T cells expressed mutant HIV-1NL4-3Pol (lane 5) or HIV-1NL4-3Nef Pol
(lane 6) viruses or coexpressed mutant HIV-1NL4-3Nef Pol virus and NefF12 (lane 7) or mutant NefKKXX (lane 8) proteins. Arrows indicate
the Gag (55 kDa) and MACA (capsid, matrix) (41 kDa) precursors, the CA (24 kDa) and Nef (27 kDa) proteins, and the 57-kDa CD8.Nef chimera.










expressing only Gag and not GagPol, and therefore lacking the
viral PR responsible for Gag processing, was coexpressed in
293T cells with the NefF12 or NefKKXX mutant proteins. Our
results demonstrate that both NefF12 and mutant NefKKXX
proteins had no effect on the expression of Gag in transfected
cells or on the production of VLPs containing only Gag (Fig.
1C, right panels; compare lane 6 to lanes 7 and 8 for virion and
lysate). In this experiment, a mutant HIV-1NL4-3 virus express-
ing only Gag (VLP) was used as the positive control (Fig. 1C,
right panels, lane 5). Levels of Nef were similar to those in
the previous experiment with HIV-1NL4-3 or mutant HIV-
1NL4-3Nef with mutant CD8.NefF12 or CD8.NefKKXX chi-
meras (Fig. 1C, bottom panel). We conclude that effects of
NefF12 and mutant NefKKXX proteins are specific for Gag
processing and relate directly to the expression of GagPol.
Importantly, the effects of the mutant CD8.NefKKXX chi-
mera and mutant NefKKXX proteins were even more pro-
nounced than those of the CD8.NefF12 chimera or NefF12
(Fig. 1B [compare lanes 3 and 4 in the left panel to lanes 7 and
8 in the right panel] and C [compare bars 3 and 4 in the
graph]), possibly due to its greater stability in 293T cells (Fig.
1B, bottom panel; compare lanes 7 and 8 to Fig. 1C, bottom
panel, lanes 3 and 4, Western blotting for Nef). As we reported
previously (12), NefF12 is very unstable in cells (Fig. 1C, bot-
tom panel, lane 3). We conclude that the addition of a KKXX
signal to the C terminus of Nef fully reconstitutes the NefF12
FIG. 1—Continued.










phenotype on Gag processing and virion production and that
the retention of Nef during biosynthetic transport is critical for
its inhibitory effects.
Nef binds GagPol in GST pull-down assays. Since retention
of the mutant CD8.NefKKXX and NefKKXX chimeras along
the biosynthetic pathway was sufficient to inhibit processing of
Gag and GagPol, we reasoned that the most likely mechanism
for this inhibition would be physical targeting of one of these
viral structural components by Nef. In initial experiments, a
160-kDa band was immunoprecipitated with the CD8.Nef fu-
sion protein from metabolically labeled cells coexpressing it
and the HIV-1NL4-3Nef proviral DNA. This band associated
with Nef also in the absence of Env gp160, suggesting that it
might represent the 160-kDa GagPol precursor (data not
shown). To investigate this possibility, studies of binding be-
tween Nef and Gag or GagPol were performed. First, GST
pull-down assays were performed with a GST.Nef fusion pro-
tein and 35S-labeled Gag, GagPol, and their truncated deriva-
tives, which were transcribed and translated in vitro by using
the rabbit reticulocyte lysate (Fig. 2A). As shown in Fig. 2B,
FIG. 2. Nef binds GagPol and p6*PR polypeptides in GST pull-down assays. (A) Shown are the frameshifted, protease-negative GagPol
(fsGagPolPR) and Gag polyproteins and their truncated derivatives. MA, CA, NC, p6, PR, RT, RT, RNase H (RH), the spacer peptides p2 and
p1, and p6* are shown. Note that p6 and p6* (frameshifted p6), which share no similarity in their sequences, are present only in Gag and GagPol,
respectively. Black lines represent the truncated GagPol and Gag precursors. GagPol and its truncated derivatives contained an inactive protease
(PR). The plus and minus signs next to each polyprotein reflect its binding to the GST.Nef chimera (data not shown). (B) GST and GST.Nef
fusion proteins were expressed in E. coli and purified from GST beads (bottom panel, Coomassie blue staining). They were incubated with
35S-labeled Gag, GagPol, or their truncated derivatives, which were transcribed and translated in vitro by using the rabbit reticulocyte lysate. Bound
proteins were resolved by SDS–10% PAGE followed by autoradiography. Shown are three examples of GST pull-down assays. Arrows indicate the
160-kDa GagPol, the 115-kDa Pol, and the 17-kDa p6*PR polyproteins. GST was used as the negative control (lanes 2, 8, and 14).










none of the proteins bound GST alone (compare lanes 2, 8,
and 14). Although we could not observe any binding between
Gag and the GST.Nef chimera (Fig. 2A), it was clear that
GagPol bound Nef (Fig. 2B, lane 3). Similar binding between
GagPol and the hybrid GST.NefF12 protein was also observed
(data not shown). To determine which regions in GagPol are
important for its binding to Nef, several truncated GagPol
proteins were synthesized. Figure 2A shows a summary of the
mapping done with GagPol. First, IN and RT were dispensable
for this binding to Nef. Likewise, Nef bound GagPol lacking
MA and CA. In sharp contrast, Pol lacking the p6* region no
longer bound Nef (Fig. 2B; compare lanes 9, 10, and 11 with
lane 7). Finally, Nef retained the p6*PR fragment derived
from GagPol (Fig. 2B; compare lanes 12 and 13). Since Nef did
not bind PR alone, we conclude that Nef binds p6* from
GagPol in vitro.
To determine which region in Nef was required for this
binding, its N- and C-terminal portions were expressed indi-
vidually as GST fusion proteins (Fig. 2B, bottom panel, Coo-
massie blue staining of GST and GST.Nef fusion proteins).
While there was no binding between GagPol and the N termi-
nus of Nef (residues 1 to 60), the C terminus of Nef (residues
55 to 210) still bound GagPol (Fig. 2B; compare lanes 4 and 5
with lane 3 for the binding of GagPol to the full-length hybrid
GST.Nef protein). Moreover, a mutant GST.Nef chimera lack-
ing the C-terminal flexible loop (NefFL from positions 148 to
180) did not bind GagPol or the p6*PR fragment (Fig. 2B,
lanes 6 and 15, respectively). We conclude that Nef specifically
binds the p6* region of GagPol via its C-terminal flexible loop
in vitro.
Nef binds GagPol and p6* in cells. Since we demonstrated
that Nef binds the p6* region of GagPol in vitro, we also
wanted to determine if this binding occurs in cells. Coimmu-
noprecipitation experiments were performed with 293T cells
that expressed various HIV-1NL4-3 proviral DNAs. Based on
our previous results, we expected that only GagPol would in-
teract with Nef. Moreover, p6* should be required for this
binding (Fig. 2). Due to the relatively low levels of expression
of GagPol and its cleavage by PR, proviruses harboring a
protease-inactivating point mutation at the active site (D25N)
were used. Moderate amounts of Nef could be detected in
anti-Gag immunoprecipitations from cells coexpressing Gag,
GagPol, and Nef (Fig. 3A, middle panel, lane 3). We then used
a mutant HIV-1NL4-3 provirus that in addition to the D25N
also contained a series of mutations in the transframe region,
which led to the exclusive expression of GagPol but not Gag
(Fig. 3A, bottom panel; compare lanes 3 and 4). In this sce-
nario, binding of Nef was observed by its coimmunoprecipita-
tion with GagPol with an anti-RT antibody (Fig. 3A, top panel,
lane 4). Furthermore, by using a HIV-1NL4-3 provirus with RT
and IN deleted, we confirmed that GagPR within GagPol is
sufficient for binding to Nef (Fig. 3A, middle panel, lane 5).
Indeed, no interaction was detected between Nef and Gag
(Fig. 3A, middle panel, lane 2). From these results, we con-
clude that Nef also binds GagPol in cells.
Next, we confirmed that p6* mediates the binding between
GagPol and Nef in cells. Figure 3B shows the coimmunopre-
cipitation with the anti-HA antibody of an HA epitope-tagged
p6* protein and Nef from 293T cells (Fig. 3B, middle panel,
lane 1). In parallel, we were unable to detect any binding
between Nef and an HA epitope-tagged p6 protein (Fig. 3B,
middle panel, lane 3). Given the differences in inputs of Nef
between Fig. 3A and B, the binding between Nef and p6* or
GagPol was equivalent in vitro and in vivo. Taken together,
these results confirm that Nef specifically binds GagPol from
HIV-1 and that p6* is required for this binding.
Mutant NefFLKKXX protein no longer interferes with Gag
processing or virion production, and mutant NefFL protein
is not incorporated into viral particles. Next, we investigated
whether the binding between Nef and GagPol plays a func-
tional role in the action of interfering Nef proteins. To this
end, a deletion of the C-terminal flexible loop was introduced
in the mutant NefKKXX protein, and its ability to interfere
with Gag processing and virion production was examined. In-
deed, the mutant NefFLKKXX protein was unable to block
virion production from cells coexpressing HIV-1NL4-3Nef
(Fig. 4A, left panel; compare bar 3 with bars 2 and 4 and with
Fig. 1C, lane 4), despite comparable levels of the mutant and
wild-type Nef proteins (Fig. 4A, right panel; compare lanes 7
and 8). Additionally, normal processing of Gag was observed in
the presence of this mutant protein (Fig. 4A; compare lane 7
with lanes 6 and 8 and with Fig. 1C, middle panel, lane 4).
Finally, the mutant NefFL protein was no longer incorporat-
ed into progeny virions (Fig. 4B; compare lane 2 to lanes 3 and
4), despite equivalent levels of virion production (Fig. 4B, bot-
tom panel, virion). Thus, the binding between Nef and GagPol
is required for the interfering effects of the mutant NefKKXX
protein. Moreover, mutant Nef protein that no longer binds
GagPol is also not incorporated into new viral particles.
Nef.Tsg101 but not mutant NefFL.Tsg101 chimeras rescue
the budding and release of mutant proviruses lacking the PTAP
motif in p6. Finally, we addressed the question of whether the
interaction with GagPol is also relevant for the physiological
function of noninterfering Nef proteins. We took advantage of
a trans-complementation assay for viral budding developed by
Martin-Serrano and colleagues (32). In this assay, budding of
new virions from a late-domain-inactive (L) provirus harbor-
ing two mutations at p6 (P7L and P10L [both mutations were
silent in p6*]) can be rescued by adding minimal late-domain
motifs to a mutant proviral DNA that lacks p6 and pol (ENX).
The requirement for the rescue of virion budding is the
recruitment of the host protein Tsg101 to the site of virion
assembly (32) (Fig. 5A, panels 1 to 3). Instead of using the
ENX plasmids with the minimal late-domain motifs (ENXp6)
to rescue viral budding, we used a Nef.Tsg101 fusion protein.
In this scenario, via its interaction with GagPol, Nef should
target Tsg101 to the site of virion assembly, thereby restoring
the budding of new virions (Fig. 5A, panel 4). As expected,
expression of the late-domain-inactive L viruses along with
the Nef.Tsg101 fusion protein rescued the release of viral
particles to the levels of HIV-1NLHXB in HeLa cells (Fig. 5B;
compare lanes 2, 5, and 7 to Fig. 5C, lanes 1, 2, and 5).
Importantly, levels of virion production were equivalent to
those achieved upon the expression of ENXp6 (Fig. 5B and C;
compare lanes 4 and 5). Thus, Nef can target Tsg101 to the
sites of viral budding.
To demonstrate that this rescue was due to the binding
between Nef and GagPol and not only to the targeting of Nef
to lipid rafts at the plasma membrane (53), a Nef protein with
a deletion in the C-terminal flexible loop and therefore unable










to bind to GagPol (Fig. 2B, lanes 6 and 15) was fused with the
Tsg101 protein to generate the mutant NefFL.Tsg101 chi-
mera. Figure 5B and C demonstrate that this hybrid protein
did not rescue viral budding from the late-domain-inactive L
virus (compare lanes 4, 5 and 6). Levels of expression of
Nef.Tsg101 and mutant NefFL.Tsg101 chimeras were iden-
tical (Fig. 5B, bottom panel, lanes 5 and 6). To confirm more
precisely that the trans-complementation of L by the
FIG. 3. Nef binds GagPol and p6* in cells. (A) Genomic regions of Gag and GagPol from HIV-1NL4-3 are represented as in Fig. 2. Gag which
contained a deletion in the pol open reading frame was used for the expression of only Gag. Gag/GagPol directed the expression of Gag and GagPol.
GagPol bears mutations in the ribosomal frameshifting site (TTTTTT3CTCCTC) and expressed only GagPol (indicated by brackets between NC and
p6*). GagPR contained a stop codon at the end of the pr open reading frame and encodes only GagPR. PR in all these polyproteins was inactive
due to the mutation of aspartate to alanine at position 25 in its active site. For coimmunoprecipitations, these proviruses were expressed in 293T cells.
Cells were lysed in RIPA buffer, followed by incubation with anti-CA (CA) polyclonal (for Gag, Gag/GagPol, and GagPro) or anti-RT monoclonal (for
Gag/GagPol and GagPol) antibodies. After the immunoprecipitation, Western blotting (WB) was performed with the anti-Nef antibody (middle panel).
A control Western blotting for protein inputs was performed with anti-CA and anti-RT antibodies and represents 50% of the input proteins (bottom
panel). Immunoprecipitation of Gag was used as the negative control for the binding between Nef and GagPol (lane 2). (B). Shown are p6 and p6*. p1
is the coding region where the frameshifting sites are located. Note that the p6* open reading frame starts in p1 (the arrow indicates the frameshifting
position) and is flanked by NC at the N terminus and by PR at the C terminus. The first amino acid residues of p6 and p6* are represented by boldface
letters. HA epitope-tagged p6 and p6* proteins were expressed alone or coexpressed with wild-type NefNL4-3 protein in 293T cells. Cells were lysed and
immunoprecipitated with the anti-HA polyclonal antibody. Immune complexes were processed as described above, and Western blotting was performed
with the anti-Nef antibody (middle panel). A control Western blot for protein input was performed with the anti-HA antibody (bottom panel).
Immunoprecipitation of p6 was used as the negative control for the binding between Nef and p6* (lane 3). Arrows indicate the 27-kDa Nef protein, the
6-kDa p6 and p6* proteins, the 55-kDa Gag protein, and the 160-kDa GagPol and 72-kDa GagPR precursors.










Nef.Tsg101 chimera was due to direct binding to GagPol and
not only recruitment of Nef to lipid rafts at the membrane,
ENX was coexpressed with the Nef.Tsg101 chimera and the
production of VLPs was analyzed 48 h later. In this experi-
ment, ENXp6 was used as a positive control for VLP produc-
tion. Although the same levels of expression of ENXp6 and
ENX were achieved in cells (Fig. 5D, bottom panel; compare
lanes 1 and 3 to lane 2), the production of VLPs from cells
expressing only ENX or coexpressing ENX and the Nef.Tsg101
chimera was decreased equivalently (Fig. 5D, top panel; com-
pare lanes 1 and 3 to lane 2). From these results, we conclude
that the Nef.Tsg101 chimera rescues late-domain-defective
proviruses only via interactions with GagPol.
DISCUSSION
This study demonstrates that the retention of Nef during its
biosynthetic pathway in the intermediate compartment inhibits
Gag processing and virion production. Importantly, by intro-
ducing an ER targeting signal, the wild-type NefNL4-3 protein
could be made into an interfering protein for viral replication.
This interference correlated with the binding between the flex-
ible loop in Nef and p6* within GagPol in vitro and in vivo.
Furthermore, since only the wild-type Nef.Tsg101, and not a
mutant NefFL.Tsg101 chimera, rescued the release of mu-
tant HIV-1 proviruses lacking a functional late domain and
since the mutant NefFL protein was no longer incorporated
into virions, this binding was biologically relevant. We con-
clude that Nef binds GagPol during the production of new
virions.
In previous studies, the perinuclear localization of NefF12
correlated with its interfering phenotype (12, 35). Thus, we
asked whether the addition of an ER retention signal to the C
terminus of a Nef protein from a common HIV-1 strain could
recapitulate this phenotype. Indeed, we demonstrated that the
hybrid mutant CD8.NefKKXX or NefKKXX proteins inter-
fered with Gag processing and virion production of a mutant
HIV-1NL4-3Nef provirus (Fig. 1B and C). Although we chose
a mutant HIV-1NL4-3Nef provirus that lacked the nef gene to
eliminate the competition with Nef encoded by the provirus,
our results could be reproduced with the wild-type HIV-1NL4-3
provirus (data not shown). Importantly, the mutant NefKKXX
protein inhibited efficiently Gag processing and virion produc-
tion in 293T cells (Fig. 1C), demonstrating that the CD8 trans-
membrane domain did not contribute to this phenotype. No-
tably, these effects were even more pronounced than those of
the hybrid CD8.NefF12 protein. Most likely, this finding re-
flects the greater stability of mutant NefKKXX proteins in
cells. Recently, a truncated nerve growth factor receptor
(NGFr).NefF12 hybrid protein was found to provide intra-
cellular immunity against HIV-1 (33). However, the expression
levels of this chimera were also relatively low, and its ability
FIG. 4. Mutant NefFLKKXX protein no longer interferes with
Gag processing or virion production, and mutant NefFL protein is
not incorporated into viral particles. (A) Virion production from 293T
cells, which expressed HIV-1NL4-3 (bar 1) or HIV-1NL4-3Nef (bar 2)
or coexpressed HIV-1NL4-3Nef and the mutant NefFLKKXX (bar
3) or the wild-type Nef (bar 4) proteins, was measured by CA capture
ELISA. Means and standard deviations from three independent ex-
periments are shown. Western blotting of these cell lysates was per-
formed with anti-CA and anti-Nef antibodies. Arrows indicate the Gag
(55 kDa) and MACA (41 kDa) precursors and the CA (24 kDa) and
the Nef (27 kDa) proteins. (B) Nef lacking the flexible loop (NefFL)
is not incorporated into progeny virions. From culture supernatants, viri-
ons were separated by centrifugation through a sucrose cushion and
examined for the presence of Gag and Nef by Western blotting. Arrows
point to different Nef proteins in cell lysates (top panel) and virions
(middle panel) as well as structural proteins in virions (bottom panel).










to inhibit the replication of diverse clinical isolates was vari-
able. Because of its greater stability, the use of the mutant
NefKKXX rather than NefF12 proteins might be advanta-
geous for such intracellular immunization.
Because hybrid mutant CD8.NefKKXX and Nef.KKXX pro-
teins blocked Gag processing, this finding implied that GagPol
is a target of Nef. Indeed, Nef bound GagPol, but not Gag,
via its C-terminal flexible loop (Fig. 2). The specificity of this
binding is explained because Nef bound p6* in GagPol, which
is not present in Gag. Importantly, our data in vitro were
confirmed in cells, in which both GagPol and p6* coimmuno-
precipitated Nef (Fig. 3). Furthermore, the interaction of
FIG. 5. The Nef.Tsg101 chimera but not the mutant NefFL.Tsg101 chimera rescues mutant HIV-1 in the PTAP motif of the late domain. (A)
Schematic representation of the trans-complementation assay for virus release. By recruiting Tsg101 to the PTAP domain of viral protein p6, cells
expressing the HIV-1NLHXB provirus are able to release new virions to the supernatant (panel 1). To create the L proviral clone, the two prolines
in the PTAP motif in p6 of HIV-1NLHXB were mutated to leucines (PTAP3LTAL). Cells expressing the L provirus no longer release virions
to the supernatant (panel 2). To rescue this release, this L mutant provirus was coexpressed with compensatory late domains (added back to a
HIV-1NLHXB mutant, named ENX, with p6, pol, vif, vpr, and nef deleted) in 293T cells (panel 3). In another scenario, the L provirus was
coexpressed with a plasmid expressing the Nef.Tsg101 chimera (panel 4). (B) Cellular supernatants were harvested, and virions were precipitated
by ultracentrifugation. Western blotting of virion preparations and cell lysates were performed with the anti-CA antibody. Lysates were also
analyzed by Western blotting with the anti-Nef antibody for the presence of the Nef.Tsg101 chimera. Arrows indicate the Gag (55 kDa) and MACA
(41 kDa) precursors, the CA (24 kDa) protein, and the Nef.Tsg101 (	83 kDa) and the NefFL.Tsg101 (	80 kDa) chimeras. (C) An aliquot of
each virion preparation was used to determine amounts of virus present in supernatants of transfected cells (RT). The wild-type HIV-1NLHXB (bar
1) and the L proviruses plus ENX.p6 (bar 4) were used as positive controls for virion production. The L provirus plus the plasmid ENX were
used as negative control for the trans-complementation assay (bar 2). The mutant NefFL.Tsg101 fusion protein (bar 6) was used as the negative
control for the binding between HIVNef and GagPol (bar 5). (D) The Nef.Tsg101 chimera does not rescue the release of VLPs from ENX. VLPs
from supernatants of cells expressing ENX, expressing ENX.p6 as a positive control, or coexpressing ENX with the Nef.Tsg101 chimera were
collected and purified. Viral and cell-associated proteins were analyzed by Western blotting with the anti-CA antibody. Arrows indicate the Gag
(55 kDa) and mutant Gagp6 (49 kDa) proteins. The presence of the Nef.Tsg101 chimera was also confirmed.










Nef and GagPol was observed in the context of normal levels
of proteins expressed from the provirus. Importantly, the
Nef.Tsg101 chimera rescued the release of viral particles from
a provirus lacking the late domain. This finding indicates that
Nef binds GagPol at sites of virion assembly. The specificity of
this assay was confirmed by the inability of the Nef.Tsg101
fusion protein to affect VLPs containing only Gag and the
mutant NefFL.Tsg101 chimera to promote the release of
complete viral particles. Thus, specific binding between Nef
and GagPol rather than incidental coaggregation of both pro-
teins in lipid rafts during viral budding was required in this
trans-complementation assay. Therefore, these results are in
agreement with a functional role for Nef and its interaction
with GagPol during virion assembly.
The interaction of the C-terminal flexible loop in Nef with
p6* in GagPol might also explain the phenotype of NefF12.
The data presented demonstrate that only the retention of
GagPol is needed for NefF12 to significantly reduce Gag pro-
cessing and virion production. Therefore, the p72/p75 proteins
that specifically interact with NefF12 (12) likely mediate the
retention and possibly degradation of this complex within the
intermediate compartment in cells. These results reveal that
the NefF12 phenotype does not result from atypical gain of
function but rather reflects the property of Nef binding GagPol
in infected cells. The inhibitory effects of ER-retained Nef
proteins then result from retention and degradation of com-
plexes between Nef and GagPol. This effect is reminiscent of
that of mutations in the PR (23) and IN (4) regions of GagPol
that generate dominant negative proteins for the production
and release of progeny virions. Retention of GagPol may syn-
ergize with the functional interaction of NefF12 with the cyto-
plasmic tail of gp41 to the complete block of HIV-1 replication
in CD4-positive cells (35).
The misrouting of GagPol by NefF12 is determined by the
three amino acid changes specific to this Nef variant (8, 12).
Importantly, all mutations in NefF12 lie outside the flexible
loop (8, 16), which still binds GagPol with the same affinity as
that of NefNL4-3 in vitro (data not shown). The C-terminal
flexible loop in Nef has been implicated in binding of many
cellular sorting proteins containing armadillo repeats, such as
the -chains of AP complexes (3, 19), the  subunit of the
COP-I coatomer (41), and subunit H of the vacuolar ATPase
(V1H) to internalize CD4 from the cell surface (18, 28, 31).
The interaction of Nef with p6* may be of a similar nature on
the molecular level. Since Nef augments virion infectivity in a
manner that depends on the flexible loop in the absence of
CD4 (29), it is possible that the binding of the flexible loop of
Nef to GagPol is critical for this effect. Whether Nef still
internalizes CD4 when associated with p6* will have to be
determined. Thus, our findings suggest that Nef and its C-
terminal flexible loop in particular might have different roles
during early and late phases of the viral replicative cycle.
Several observations support a role for the interaction of Nef
with GagPol in the replication of HIV-1. First, Ono et al. (38)
demonstrated that a deletion of Nef had different effects in two
highly related proviruses (HIV-1LAIBru and HIV-1NL4-3), in
which viral replication for only one provirus (HIV-1NL4-3) de-
pended on Nef. Importantly, GagPol (minimally a region con-
taining the NC.PR) was responsible for this difference. Anal-
yses of GagPol from these two proviruses confirmed that
although their sequences are highly conserved, with the nef
genes sharing 98% similarity, p6* from HIV-1LAIBru had an
insertion of two residues followed by a duplication of 10 resi-
dues near the N terminus. This finding suggests genetically a
link between Nef and p6* in GagPol. Second, when Nef from
HIV-1 is introduced into the simian immunodeficiency virus
SIVmac239, the resulting chimeric virus replicates poorly in
rhesus macaques until mutations in Nef are observed (30).
One study describes the accumulation of such compensatory
changes in the C-terminal flexible loop of Nef. Although fur-
FIG. 5—Continued.










ther mutations were observed in the transmembrane portion of
Env, GagPol was not examined (2). The flexible loop in SIV
Nef is also a key determinant for SIV infectivity in human
lymphocytes (31), and the ability of Nef to internalize CD4 (via
the flexible loop) was correlated with its role in the pathogen-
esis of simian AIDS (reference 31 and references therein).
Finally, with a truncated Nef protein that resulted from larger
deletions of the nef gene in SIVmac239, the restoration of
virion infectivity correlated with the return of the flexible loop
(6, 43). Of interest is that p6* sequences are highly divergent
between HIV-1 and SIV, and our preliminary studies reveal a
species-specific restriction to interactions between Nef and p6*
from HIV-1 and SIV (data not shown). Therefore, these find-
ings suggest that Nef and p6* are matched within the primate
lentiviruses HIV-1 and SIV and possibly HIV-2 and that the
interaction between Nef and GagPol facilitates viral replica-
tion.
Our data suggest a model for this new role of Nef in the viral
replicative cycle. Nef binds p6* in GagPol within the cyto-
plasm, probably in the context of complexes between Gag and
GagPol (see references 34 and 48 and references therein).
Therefore, GagPol likely represents the viral interaction part-
ner that allows Nef to target HIV-1 budding to these deter-
gent-resistant microdomains (53). Indeed, in the absence of
GagPol, only a small fraction of complexes containing only
Gag move to lipid rafts (21). Putative assembly intermediates
between Gag, GagPol, and Nef may be efficiently incorporated
into lipid rafts at the plasma membrane due to the presenta-
tion of multiple membrane-targeting motifs on these proteins
(21, 36, 37, 50, 53). Oligomerization of Nef (17) could help to
multimerize these assembly intermediates and thus facilitate
this incorporation. Nef also causes cytoskeletal rearrange-
ments that could further trap these lipid rafts and/or help to
form and release immature virions (13, 42). Moreover, as it
induces intracellular accumulation of multivesicular bodies,
where these detergent-resistant microdomains are formed and
from which HIV buds, Nef could also facilitate the maturation
and release of progeny virions (47). In this regard, it is of some
interest that a lentivirus that lacks Nef, the equine infectious
anemia virus, also contains a late domain in the GagPol pre-
cursor (46). Finally, Nef not only activates downstream signal-
ing cascades, which increase the biosynthesis of cholesterol,
but also carries this new cholesterol to sites of viral budding
(52). At the same time, the interaction of Nef with GagPol
ensures its incorporation in the virion. In this scenario, inter-
actions between Nef and GagPol could facilitate the produc-
tion of optimal virions for subsequent rounds of infection.
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